Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ECE2 | P0DPD6 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | PANK3 | Q9H999 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16211006 | 0.97 | KMT2A (0.52) | L3MBTL1ECE2NPC1HPGDSMN1; SMN2 | |
| SCHEMBL14084729 | 0.81 | GABRP (0.58) | ECE2NPC1HPGDSMN1; SMN2KMT2A | |
| SCHEMBL5080004 | 0.80 | PANK3 (0.49) | SMN1; SMN2KMT2AMEN1ATMPANK3 | |
| SCHEMBL7430480 | 0.78 | HPGD (0.67) | NPC1HPGDSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL12436381 | 0.78 | ECE2 (0.51) | ECE2NPC1HPGDSMN1; SMN2KMT2A | |
| SCHEMBL9528958 | 0.77 | HPGD (0.70) | NPC1HPGDSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL8163504 | 0.76 | PANK3 (0.48) | L3MBTL1HPGDSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL22217034 | 0.75 | SMN1; SMN2 (0.67) | ECE2NPC1HPGDSMN1; SMN2KMT2A | |
| SCHEMBL30154481 | 0.74 | GABRP (0.61) | L3MBTL1NPC1KMT2AMEN1ATM | |
| SCHEMBL256024 | 0.74 | GABRP (0.61) | L3MBTL1NPC1KMT2AMEN1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137162-B1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2018-08-01 | — | — | EP | disclosed |
| US-8536168-B2 | Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | disclosed |
| US-20100069368-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069368-A1 | Organic Compounds and Their Uses | SHH, GLI1, VHL | L3MBTL1 1097/4885ECE2 2220/4885NPC1 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.